Dynamical models of mutated chronic myelogenous leukemia cells for a post-imatinib treatment scenario: Response to dasatinib or nilotinib therapy

Targeted inhibition of the oncogenic BCR-ABL1 fusion protein using the ABL1 tyrosine kinase inhibitor imatinib has become standard therapy for chronic myelogenous leukemia (CML), with most patients reaching total and durable remission. However, a significant fraction of patients develop resistance,...

Descripción completa

Detalles Bibliográficos
Autores principales: Woywod, Clemens, Gruber, Franz X., Engh, Richard A., Flå, Tor
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5497988/
https://www.ncbi.nlm.nih.gov/pubmed/28678800
http://dx.doi.org/10.1371/journal.pone.0179700

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5497988/
https://www.ncbi.nlm.nih.gov/pubmed/28678800
http://dx.doi.org/10.1371/journal.pone.0179700

Ejemplares similares